Reply to letter to editor “Public health impact and cost-effectiveness of the adjuvanted RSVPreF3 vaccine for respiratory syncytial virus prevention among adults aged 50 years and older in Germany”

Expert Review of Vaccines 2026 Open access

Read full text
Authors: Maria Waize, Pavo Marijic, Alen Marijam, Foteini Gkalapi, Elisa Turriani, Franziska M. Jakobs, Indra Jaidhauser, Dorothea Münch, Sara Pedron, Eleftherios Zarkadoulas
DOI: 10.1080/14760584.2025.2606342
Cited by: 0
References: 12

Abstract

Dear editor,In their letter to the editor, the authors comment on our recent work, which estimates the public health impact and cost-effectiveness of adjuvanted RSV prefusion F protein (RSVPreF3) v...

Fields of Study & Subjects

Respiratory viral infections research Immune responses and vaccinations Virology and Viral Diseases

Publication details

Journal / source
Expert Review of Vaccines
Volume
25
Issue
1
Pages
2606342–2606342
Publication date
5 January 2026
Language
EN